
Joao Seraphim
Citing preliminary financials, TG Therapeutics (NASDAQ:TGTX) announced Tuesday that U.S. net sales of its multiple sclerosis therapy, Briumvi, for the fourth quarter and full year 2024 far exceeded its initial projections.
Following a presentation at the ongoing JP Morgan Healthcare Conference in San






